Effect of vasoactive intestinal peptide (VIP)-related peptides on cholinergic neurogenic and direct mucus secretion in ferret trachea in vitro.
1 We investigated whether vasoactive intestinal peptide (VIP) and its related peptides, pituitary adenylate cyclase activating peptide (PACAP) and secretin, regulate cholinergic neural mucus secretion in ferret trachea in vitro, using 35SO4 as a mucus marker. We also studied the interaction between VIP and secretin on cholinergic mucus output. 2 VIP (1 and 10 microM) increased secretion, whereas neither PACAP1 - 27, PACAP1 - 38 nor secretin (up to 10 microM) increased mucus output. In contrast, VIP, PACAP1 - 27 and PACAP1 - 38 concentration-dependently inhibited cholinergic neural secretion, with an order of potency of VIP>PACAP 1 - 38>PACAP1 - 27. Neither PACAP1 - 27 nor PACAP1 - 38 altered the secretion induced by acetylcholine (ACh). 3 Secretin increased cholinergic neural secretion with a maximal increase of 190% at 1 microM. This potentiation was blocked by VIP or atropine. Similarly, secretin (1 microM) potentiated VIP (1 microM)-induced mucus output by 160%. Secretin did not alter exogenous ACh-induced secretion. VIP vs secretin competition curves suggested these two peptides were competing reversibly for the same receptor. 4 We conclude that, in ferret trachea in vitro, VIP and PACAPs inhibit cholinergic neural secretion via pre-junctional modulation of cholinergic neurotransmission. VIP and secretin compete for the same receptor, possibly a VIP1 receptor, at which secretin may be a receptor antagonist.
Liu
Y C
YC
Thoracic Medicine II, Chang Gung Memorial Hospital, 199 Tun-Hwa North Road, Taipei, Taiwan, ROC 105.
Khawaja
A M
AM
Rogers
D F
DF
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects; D002799:Cholinergic Fibers / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004558:Electric Stimulation; D005289:Ferrets; D066298:In Vitro Techniques; D008297:Male; D009093:Mucus / Q000187:drug effects* / Q000378:metabolism; D009479:Neuropeptides / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D011433:Propranolol / Q000494:pharmacology; D018005:Receptors, Vasoactive Intestinal Peptide / Q000378:metabolism; D012633:Secretin / Q000494:pharmacology; D014132:Trachea / Q000187:drug effects* / Q000294:innervation / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D009479:Neuropeptides; D010880:Piperidines; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D018005:Receptors, Vasoactive Intestinal Peptide; C080755:3-(2-methoxybenzylamino)-2-phenylpiperidine; D012633:Secretin; D014660:Vasoactive Intestinal Peptide; D001285:Atropine; D011433:Propranolol; D000109:Acetylcholine; D010646:Phentolamine